<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561532</url>
  </required_header>
  <id_info>
    <org_study_id>HUS / 1652/2016</org_study_id>
    <nct_id>NCT03561532</nct_id>
  </id_info>
  <brief_title>Fecal Transplantation in Ulcerative Colitis</brief_title>
  <acronym>FMT-CU</acronym>
  <official_title>FECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF ULCERATIVE COLITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult individuals with ulcerative colitis in remission are given a single fecal microbiota
      transplantation (FMT) in colonoscopy. A half of the patients will receive autologous FMT as a
      placebo and a half will receive an FMT from a healthy donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 adult patients with ulcerative colitis (UC) will be recruited. They are randomized to
      receive either an autologous FMT as a placebo or FMT from a healthy donor (frozen and
      thawed).

      The patients are followed up with fecal samples to detect microbial changes. The follow up
      lasts 1 year after the FMT and a follow up colonoscopy will be done 52 weeks after the FMT.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomized in two groups to receive in colonoscopy either a fecal suspension made of their own feces or a fecal suspension of a healthy donor.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant and the treating personnel are blinded of the randomization result.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of remission of ulcerative colitis</measure>
    <time_frame>52 weeks</time_frame>
    <description>Endoscopic remission and Mayo-score &lt; 2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal microbiota transplantation (FMT)</intervention_name>
    <description>FMT administered into the cecum of the patient in colonoscopy.</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • • Diagnosis of CU based on clinical, endoscopic, and histological findings.

               -  Remission assessed by Mayo score (0 to 1) and F-Calpro (&lt;100 ug/g).

               -  Availability of consecutive fecal samples during one year after the diagnosis of
                  CU.

               -  Availability of blood sample to study the IBD associated genetic background

               -  Compliance to attend ileocolonoscopy and FMT within 3-6 months after the
                  diagnosis of CU and at 52 week

               -  18-75 years

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Need for any antibiotic therapy within 3 months

          -  Use of corticosteroids, immunosuppressive or biological medication at the baseline

          -  Use of any probiotics

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

